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Abstract: The increasing prevalence of type 2 diabetes provides impetus for both development 
of new drugs to improve glycemic control and for reconsideration of treatment strategies with 
existing agents. Combination therapy with complementary drug classes that act on different 
aspects of glycemic control has been a particularly effective strategy. This work reviews the 
published literature reporting efﬁ  cacy and safety/tolerability of nateglinide, a rapid-onset insu-
linotropic agent with a predominant effect to reduce postprandial glucose, when combined with 
metformin, a ﬁ  rst-line agent that suppresses hepatic glucose production and thereby reduces 
fasting plasma glucose. The nateglinide/metformin combination has consistently been found 
to be both efﬁ  cacious and well tolerated, whether given as initial combination therapy in drug-
naïve patients or when added to metformin monotherapy. Maximum efﬁ  cacy (Δ glycosylated 
hemoglobin [HbA1c] = –1.4% to –1.9%, sustained for up to 2 years of treatment) was seen in 
studies of drug-naïve patients in whom pharmacotherapy was initiated with the combination of 
nateglinide and metformin, and modest reductions in HbA1c (Δ = –0.5% to –1.2%, sustained for 
up to 24 weeks) were found when nateglinide was added to ongoing metformin monotherapy. 
Conclusion: the combination of nateglinide and metformin provides a sustained degree of 
glycemic control not achievable with either agent given as monotherapy.
Keywords: metformin, nateglinide, combination therapy, type 2 diabetes, postprandial 
hyperglycemia
Introduction
The total prevalence of diabetes in the United States (both diagnosed and undiagnosed) 
is estimated to be 7%, representing 20.7 million people (Centers for Disease Control 
and Prevention 2005). Population models based on data from the National Health and 
Nutrition Examination Survey (NHANES) project a diabetes burden of 14.5% of the 
total population (37.7 million people) by 2031 (Mainous et al 2007). Globally, the 
prevalence of diagnosed diabetes was estimated to be 2.8% in 2000 (171 million 
people) and is projected to rise to 4.4% by 2030 (366 million people) (Wild et al 
2004). Moreover, it should be recognized that for every 2 people with known diabetes 
there is another with undiagnosed diabetes. This epidemic of diabetes is driven by 
Westernization in developing countries, by the increasing prevalence of obesity, and 
by the aging of the global population (Wild et al 2004). Models based on NHANES 
and census data project that, at age 18, the lifetime risk of developing diabetes exceeds 
50% in obese individuals (body mass index [BMI]  30 but  35 kg/m2) (Narayan 
et al 2007).
The health-care burden that would be imposed by treating the medical consequences 
of diabetes in such large numbers of patients is enormous and has given impetus Vascular Health and Risk Management 2008:4(6) 1168
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for the development of new drugs to treat type 2 diabetes 
(T2DM, accounting for 90%–95% of all diabetes) more effec-
tively and to a reconsideration of treatment strategies with 
existing agents. Diabetes is difﬁ  cult to control with a single 
oral agent. Many patients fail to achieve adequate glycemic 
control (glycosylated hemoglobin [HbA1c]  7.0%) with 
monotherapy (particularly those with high baseline values) 
and even of those initially achieving good control, less than 
half will maintain this target level for 2 years (Cook et al 
2007). Such observations have stimulated the development of 
combination therapies that match drugs with complementary 
mechanisms of action in the hope of obtaining better and 
longer-lasting glycemic control.
Rationale for combining metformin 
and nateglinide
Type 2 diabetes is a chronic, progressive disorder that results 
from inadequate β-cell compensation for, or adaptation to, 
insulin resistance (Kahn 2003). Thus, both insulin resistance 
and β-cell dysfunction precede the development of overt 
diabetes (Weyer et al 1999). Furthermore, with increasing 
severity of glycemic dysregulation, the progressive decline in 
β-cell function is accompanied by an increasingly important 
contribution of excessive hepatic glucose production (HGP) 
(DeFronzo et al 1989). Not surprisingly, therefore, no single 
oral antidiabetic drug (OAD) has been found to provide 
adequate, prolonged glycemic control as diabetes progresses, 
and there is a strong scientiﬁ  c rationale for combining OADs 
with complementary modes of action, ie, that target different 
pathogenetic factors.
Metformin, a biguanide, acts by decreasing HGP and 
increasing glucose clearance (Natali et al 2006); it is the 
recommended ﬁ  rst-line pharmacologic treatment for T2DM 
worldwide (Nathan et al 2006). Metformin primarily reduces 
fasting plasma glucose (FPG); it has no direct effect on β-cell 
function, and it is ineffective in the absence of insulin (Bailey 
et al 1996). In patients with moderate- to poorly-controlled 
T2DM, metformin monotherapy was found to decrease 
FPG by 60 mg/dL to 70 mg/dL and HbA1c by 1.5% to 2% 
(DeFronzo 1999), but only about 25% of patients achieved 
the American Diabetes Association (ADA)-recommended 
goal of  HbA1c  7.0% (DeFronzo et al 1995). Metformin has 
a very low potential to induce hypoglycemia and, as with all 
OADs, the magnitude of reduction in HbA1c is proportional 
to the baseline value.
Nateglinide is one of a newer class of OADs, the 
“glinides,” which are rapid-onset, insulinotropic agents 
unrelated to the sulfonylureas. These agents are taken before 
meals (ac) and rapidly increase insulin secretion, essentially 
restoring (or replacing) the early insulin response, which is 
lost in patients with T2DM. These agents predominantly 
decrease postprandial glucose (PPG), which is an indepen-
dent predictor of negative cardiovascular outcomes (Qiao 
et al 2002), thought to be mediated by oxidative stress 
(Ceriello 2000). Nateglinide is unique among glinides in that 
its pharmacodynamics closely match its pharmacokinetics, 
so it has both a rapid onset and short duration of action 
(McLeod 2004). Other glinides, such as repaglinide, have 
pharmacokinetics similar to those of nateglinide, but because 
of slow receptor dissociation, their insulinotropic actions 
are prolonged well beyond clearance of the drugs (Pratley 
et al 2001). This results in essentially identical reductions in 
PPG with the 2 agents, somewhat larger decreases in FPG 
and HbA1c with repaglinide than with nateglinide, but with 
substantially increased frequency of hypoglycemia with 
repaglinide than with nateglinide (Rosenstock et al 2004). 
In patients nearing glycemic targets, hypoglycemia becomes 
an increasingly important concern.
When given as monotherapy to patients with moderate- to 
poorly-controlled T2DM, nateglinide (120 mg ac) mono-
therapy reduced HbA1c by 1.0% and FPG by 18 mg/dL, with 
no hypoglycemia (Rosenstock et al 2004). Because of their 
complementary modes of action, and their very low potential 
to elicit hypoglycemia, the combination of metformin and 
nateglinide would be predicted to be both safe and effective 
for the treatment of T2DM.
The purpose of this paper is to review all available 
information about the efﬁ  cacy and safety of nateglinide 
in combination with metformin, whether used as initial 
combination therapy or with nateglinide added to ongoing 
metformin treatment.
Methods
To identify all published literature on the efﬁ  cacy and safety/
tolerability of nateglinide when combined with metformin 
in patients with T2DM, a search was performed of  Medline, 
EMBASE, Biosis Previews, Current Contents, International 
Pharmaceutical Abstracts, and Cochrane Reviews, for 
publications appearing from 1998 to 2008. The search was 
limited to English language journals and required that both 
nateglinide (or synonyms) and metformin (or synonyms) 
appear as keywords in titles or in abstracts.
Eight review articles and 25 original publications were 
identiﬁ  ed. Of the 25 original publications, 5 were abstracts 
(4 of which described studies that were subsequently 
reported in full papers, and 1 of which provided insufﬁ  cient Vascular Health and Risk Management 2008:4(6) 1169
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information to understand the study design or efficacy 
results), 4 dealt with health economics, 3 were nonclinical, 
1 described a clinical study of  12 weeks’ duration, and 
1 reported on safety but included no efﬁ  cacy data. Thus, 
only 11 publications reported original ﬁ  ndings relating to 
the efﬁ  cacy and tolerability of  12-week treatment with 
the nateglinide/metformin combination. The 8 review 
articles were obtained, and examination of their reference 
lists revealed no additional original publications describing 
the efﬁ  cacy and safety of nateglinide in combination with 
metformin.
Clinical trials of metformin/nateglinide 
combination therapy for T2DM
Table 1 summarizes the study design and efﬁ  cacy results 
from the 11 original publications. The publications include 
data from more than 12,500 patients who received nateglinide 
in combination with metformin for  16 weeks, and the mean 
baseline HbA1c levels ranged from ∼7.6% to 8.4%.
Five of the 11 publications provide results from double-
blind, randomized, controlled clinical trials (RCTs), 
2 describe analyzes of subpopulations included in blinded 
RCTs, 1 was a 6-month extension of a blinded RCT, and 
3 were open-label studies, 1 of which was an observational 
study of  11,000 patients treated under general practice 
conditions.
Randomized, double-blind trials
Five double-blind, RCTs have assessed the efﬁ  cacy and 
safety of the combination of metformin and nateglinide 
for the treatment of T2DM. Horton et al (2000) performed 
a 24-week, parallel-group study in patients randomized to 
receive nateglinide (120 mg ac, n = 179), metformin (500 mg 
tid, n = 178), nateglinide plus metformin (n = 172), or placebo 
(n = 172). Liquid meal tests were performed at baseline and 
at week 24 or endpoint, and HbA1c and FPG were measured 
periodically during the study. Participants were required to 
have been diagnosed with T2DM at least 3 months before 
study entry and to have been treated with diet/exercise 
alone during a 4-week washout period that preceded a 
4-week placebo run-in phase. At baseline (week 0), the 
mean age, BMI, duration of diabetes, HbA1c, and FPG 
of participants were ∼58 years, 29.6 kg/m2, 4.6 years, 
8.4%, and 10.9 mmol/L, respectively, and the 4 treatment 
groups were well balanced with respect to these baseline 
characteristics.  As illustrated in Figure 1, after 24-week 
treatment, HbA1c and FPG decreased signiﬁ  cantly in each 
active treatment group and increased modestly in patients 
receiving placebo, relative to baseline. Postprandial glucose, 
as assessed by the glucose area under the curve (AUC) 
during the meal test, decreased in all treatment groups. Thus, 
relative to placebo, PPG decreased signiﬁ  cantly only in the 
nateglinide monotherapy and in the combination therapy 
groups. At study endpoint, the placebo-adjusted changes 
in HbA1c were –0.9%, –1.2%, and –1.9% in the nateg-
linide, metformin, and combination groups, respectively, 
clearly showing an additive effect of nateglinide and 
metformin. Metformin monotherapy had a larger effect on 
FPG (Δ = –1.6 mmol/L) than did nateglinide monotherapy 
(Δ = –0.7 mmol/L) but, again, the effects of nateglinide and 
metformin were additive (Δ = –2.4 mmol/L). Moreover, 
essentially all of the reduction in PPG during combination 
therapy (Δ = –2.5 mmol/L•h) can be attributed to the effects 
of nateglinide (Δ = –2.1 mmol/L•h). The most common 
adverse events (AEs) were suggestive of hypoglycemia and 
diarrhea. Symptoms suggestive of hypoglycemia occurred 
most often in the combination group (26.2%) and there 
was no difference between the nateglinide and metformin 
monotherapy groups (12.8% vs 10.1%). The number of 
patients with conﬁ  rmed hypoglycemia (symptoms plus 
plasma glucose measurement  3.3 mmol/L) was very low 
– 3 patients ( 2%) in the nateglinide group, 1 ( 1%) in the 
metformin group, and 5 ( 3%) in the combination therapy 
group. Diarrhea was more common in the groups receiving 
metformin alone (19.7%) or in those receiving metformin 
combined with nateglinide (14.5%); these frequencies were 
3- to 4-times higher than in the nateglinide monotherapy or 
placebo groups. Body weight did not change signiﬁ  cantly 
relative to baseline in any treatment group. In summary, this 
study clearly demonstrated the complementary modes of 
action of nateglinide and metformin, the additive efﬁ  cacy of 
the 2 agents, and a tolerability proﬁ  le of the combination that 
did not differ from either of the monotherapy components.
In a subsequent subgroup analysis, Horton et al 
(2004) assessed the efﬁ  cacy and tolerability of metformin, 
nateglinide, and their combination in the subset of patients 
(n = 401) from their earlier trial (Horton et al 2000) who had 
not been previously exposed to any medication for diabetes. 
At baseline, the mean disease duration (∼4.0 years), 
HbA1c (8.2%), and FPG (10.2 mmol/L) in this treatment-
naïve subgroup of patients were slightly less than those 
in the entire cohort described above. In this drug-naïve 
group, the patients who received combination therapy for 
24 weeks experienced a major reduction in mean HbA1c 
(–1.6% from a mean baseline value of 8.2%; p   0.0001) that 
was signiﬁ  cantly greater than that seen with monotherapy Vascular Health and Risk Management 2008:4(6) 1170
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Table 1 Study designs and efﬁ  cacy outcomes
Reference Description of Study Efﬁ  cacy (HbA1c)
Duration Number of 
patients
Study design Treatment groups Baseline 
(%)
Endpoint or Δ 
baseline Mean ± 
SE or [95% CI]
Horton et al 
(2000)
24 wk 701 diet-
treated pts
multicenter, double-blind, 
parallel-group, RCT
Nateglinide (120 mg ac) plus 
metformin (500 mg tid)
8.4 ± 1.1 –1.4 ± 0.1a,b
Nateglinide (120 mg ac) 8.3 ± 1.0 –0.5 ± 0.1a
Metformin (500 mg tid) 8.4 ± 1.2 –0.8 ± 0.1a,b
Placebo 8.3 ± 1.1 +0.5 ± 0.1
Marre et al 
(2002)
24 wk 467 metformin-
treated pts
multicenter, double-blind, 
parallel-group, RCT
Nateglinide (120 mg ac) added 
to metformin (1000 mg bid)
8.2 –0.5 [–0.6, –0.1]a
Nateglinide (60 mg ac) added 
to metformin (1000 mg bid)
8.0 –0.4 [–0.6, –0.1]a
Placebo added to metformin 
(1000 mg bid)
8.3 0
French (2001) 16 wk 192 pts previ-
ously treated with 
Glucovance, SU, 
or metformin
multicenter, randomized, 
parallel-group, open-label 
study, following 4-wk 
washout from previous 
medication
Nateglinide (120 mg ac) added 
to metformin (titrated to 
1000 mg bid)
8.2 ± 1.3 –0.7 ± 0.1a
Repaglinide (titrated to  4 
mg ac) added to metformin 
(titrated to 1000 mg bid)
8.4 ± 1.3 –1.3 ± 0.1a,b
Schatz et al 
(2003)
3 to 4 mo 11,421 metformin-
treated pts
observational study under 
general practice condi-
tions
Nateglinide (120 mg ac) added 
to ongoing metformin (mean 
dose 850 mg bid)
8.4 ± 0.01 7.2 ± 0.01a
Horton et al 
(2004)
24 wk 401 drug-naïve pts subanalysis of drug-
naïve pts enrolled in a 
multicenter, double-blind, 
parallel-group, RCT
Nateglinide (120 mg ac) plus 
metformin (500 mg tid)
8.2 ± 0.1 –1.6 ± 0.1a,b
Nateglinide (120 mg ac) 8.1 ± 0.1 –0.8 ± 0.1a
Metformin (500 mg tid) 8.3 ± 0.1 –0.8 ± 0.1a
Placebo 8.2 ± 0.1 +0.3 ± 0.1a
Weaver et al 
(2004)
12 wk 115 diet-treated 
pts, 214 metformin-
treated pts
multicenter, open-label, 
parallel-group study
Nateglinide (120 mg ac) 8.1 ± 0.06 –0.8 ± 0.07a
Nateglinide (120 mg ac) added 
to metformin
8.1 ± 0.04 –0.7 ± 0.05a
Gerich et al 
(2005)
2 y 428 drug-naïve pts multicenter, double-blind, 
parallel-group, RCT
Nateglinide (120 mg ac) 
plus metformin (titrated to 
 1000 mg bid)
8.4 ± 1.2 –1.4 ± 0.1a
Glibenclamide (titrated to 
 5 mg bid) plus metformin 
(titrated to  1000 mg bid)
8.3 ± 1.1 –1.6 ± 0.1a
Ristic et al 
(2006)
24 wk 262 pts, 
HbA1c = 6.8%–9.0% 
on metformin 
monotherapy
multicenter, double-blind, 
parallel-group, RCT
Nateglinide (titrated to 
  120 mg ac) added to 
metformin ( 1000 mg/d)
7.7 ± 0.6 –0.4 ± 0.1a
Gliclazide (titrated to 
 240 mg qd) added to 
metformin ( 1000 mg/d)
7.6 ± 0.6 –0.6 ± 0.1a
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(–0.8% for both treatments), or with placebo treatment 
(+0.3%). Thus, the placebo-adjusted change in HbA1c in 
drug-naїve patients receiving initial combination therapy 
with nateglinide and metformin was –1.9%, and of the 
patients receiving initial combination therapy, 70% achieved 
an endpoint HbA1c of  7% compared with 34%, 41%, and 
17% in the groups receiving nateglinide monotherapy, 
metformin monotherapy, and placebo, respectively. All 
active treatments also resulted in signiﬁ  cant reductions in 
FPG (Δ = –1.1, –1.2, –2.3, and +0.2 mmol/L) and in PPG 
excursions (Δ = –1.9, –1.0, –2.3, and –0.5 mmol/L) for 
nateglinide, metformin, combination, and placebo groups, 
respectively. The AE proﬁ  le in this drug-naïve subgroup of 
patients was very similar to that seen in the whole cohort 
(described above). Marre et al (2002) evaluated the effect 
of nateglinide as an add-on to high-dose metformin in 
patients with T2DM. This 24-week, double-blind, parallel-
group RCT included 467 patients with T2DM treated with 
metformin monotherapy for  3 months who had been 
stabilized on metformin  1500 mg daily for at least 4 
weeks prior to study entry. After a 4-week run-in during 
which all patients received metformin at a dose of 1000 
mg bid, patients were randomized to receive nateglinide 
(60 mg ac, n = 155), nateglinide (120 mg ac, n = 160), or 
placebo (n = 152) added to the ongoing metformin (1000 
mg bid) monotherapy.
At baseline, the mean age, BMI, duration of diabetes, 
HbA1c, and FPG in the whole cohort were ∼57 years, 
29.4 kg/m2, 8.1%, and 9.9 mmol/L, respectively. The treat-
ment groups were well balanced with respect to these baseline 
characteristics.
Addition of nateglinide at either dose to metformin 
resulted in a signiﬁ  cant reduction of HbA1c compared with 
metformin plus placebo. The placebo-corrected reductions 
in HbA1c were –0.4% and –0.6% in the nateglinide 60-mg 
and nateglinide 120-mg groups, respectively. Larger, but 
still dose-related reductions were seen in patients with 
higher baseline HbA1c levels; in the subgroup of patients 
with a baseline value between 8% and 9.5%, the Δ HbA1c 
was –0.5% for the 60-mg dose and –0.8% for the 100-
mg dose. In the subgroup of patients with baseline level 
 9.5%, the Δ HbA1c was –0.8% and –1.4% for nateglinide 
60 mg and 100 mg, respectively, while with placebo added 
to metformin HbA1c changed by less than 0.1% in all sub-
groups of patients. Both doses of nateglinide also resulted 
in modest but signiﬁ  cant reductions in FPG compared to 
Table 1(continued)
Reference Description of Study Efﬁ  cacy (HbA1c)
Duration Number of 
patients
Study design Treatment groups Baseline 
(%)
Endpoint or Δ 
baseline Mean ± 
SE or [95% CI]
Ristic et al 
(2007)
1 y 213 pts HbA1c = 
6.8%–9.0% on 
metformin 
monotherapy
6-mo extension of a 6-mo 
multicenter, double-blind, 
parallel-group, RCT
Nateglinide (titrated to   
120 mg ac) added to 
metformin ( 1000 mg/d)
7.65 ± 0.6 –0.14
Gliclazide (titrated to   
240 mg qd) added to 
metformin ( 1000 mg/d)
7.55 ± 0.6 –0.27
Derosa et al 
(2007)
1 y 248 drug naïve pts multicenter, double-blind, 
parallel-group, RCT
Nateglinide and metformin 
(titrated to 120 mg, ac; 
1000 mg, tid)
8.1 ± 1.0 6.4 ± 0.4a,b
Glibenclamide and 
metformin (titrated to 
5 mg tid, 1000 mg, tid)
8.2 ± 1.1 7.3 ± 0.6a
Schwarz et al 
(2008)
2 y 66 drug-naïve pts 
age  65 y
subanalysis of elderly 
patients enrolled in 
multicenter, double-blind, 
parallel-group, RCT
Nateglinide and metformin 
(titrated to 120 mg, ac; 
1000 mg, bid)
7.8 ± 0.2 6.6 ± 0.1a
Glibenclamide and 
metformin (titrated to 
5 mg bid; 1000 mg, bid)
7.7 ± 0.1 6.5 ± 0.1a
ap   0.05 or better vs baseline; bp   0.05 or better vs comparator.
Abbreviations: RCT, randomized, controlled trial; HbA1c glycosylated hemoglobin.Vascular Health and Risk Management 2008:4(6) 1172
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placebo when added to metformin. Addition of 60-mg 
nateglinide to metformin had no effect on body weight, 
while treatment with 120-mg nateglinide plus metformin 
resulted in a 0.9-kg weight gain compared with treatment 
with metformin plus placebo.
The overall percentage of patients experiencing AEs was 
similar in all treatment groups (54.6%, 60%, and 58.8% in 
the metformin/placebo group, the metformin/nateglinide 
60-mg group, and the metformin/nateglinide 120-mg group, 
respectively). The most commonly reported AEs were symp-
toms suggestive of hypoglycemia (3.9%, 8.4%, and 15.6%, 
respectively). When stratiﬁ  ed by HbA1c level, most symptoms 
suggestive of hypoglycemia occurred with nateglinide 120 
mg/metformin administered to patients with low baseline 
HbA1c ( 8%). Although a blood glucose level was recorded 
in 80% of the events, very few patients (n  =  6, 1.1%) had 
conﬁ  rmed hypoglycemia, deﬁ  ned as a symptomatic event 
with a plasma glucose equivalent  3.3 mmol/L, and none 
of these hypoglycemic episodes required intervention by a 
third party. As expected, since patients had been stabilized 
on metformin monotherapy for  3 months prior to study, 
the incidence of gastrointestinal AEs was low and similar in 
all treatment groups.
A 2-year study of initial combination therapy 
(PRESERVE-β) compared the effects of nateglinide 
plus metformin (nate/met) to those of glyburide plus 
metformin (glyb/met) in drug-naïve patients with 
relatively recently diagnosed T2DM (Gerich et al 
2005). In this double-blind, parallel-group, RCT, 428 
patients received open-label metformin (500 mg qd 
titrated to 1000 mg bid if tolerated) combined with either 
nateglinide (120 mg ac, n = 219) or glyburide (1.25 mg 
qd titrated to a maximum of 5 mg bid, n = 209). Blinding 
was achieved by use of matching placebo for nateglinide 
and glyburide. At baseline, the mean age, BMI, disease 
duration, HbA1c, and FPG were ∼53 years, 33.4 kg/m2, 
1.8 years, 8.4%, and 10.0 mmol/L, respectively. The 
treatment groups were well balanced with respect to these 
baseline characteristics.
As illustrated in Figure 2, both drug combinations pro-
duced substantial and sustained reductions in HbA1c. At study 
endpoint, the mean Δ HbA1c was –1.2% in the nate/met group 
and –1.5% in the glyb/met group (p   0.0001 vs baseline for 
both groups, p = 0.1730 between groups). After 2 years of 
treatment, 39% of the nate/met group and 43% of the glyb/met 
group had achieved and maintained HbA1c  7%.
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Figure 1 Adjusted mean change from baseline in glycosylated hemoglobin (HbA1c), fasting plasma glucose (FPG), and glucose area under the curve (AUC) after Sustacal 
challenge. All parameters were signiﬁ  cantly reduced from baseline (p   0.0001) in the active treatment groups. All values were signiﬁ  cantly reduced compared to placebo 
(p   0.0001) except for glucose AUC with metformin monotherapy (not signiﬁ  cant, NS). *p   0.01; **p   0.001; ***p   0.0001. Open bars = placebo; light gray bars = nateg-
linide monotherapy; dark gray bars = metformin monotherapy; black bars = nateglinide plus metformin (Horton et al 2000). Copyright © 2000 American Diabetes Association. 
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Consistent with their known mechanisms of actions and 
established effects on FPG and PPG, glyb/met was more 
effective in reducing FPG, and nate/met was more effective 
in reducing PPG. Thus, FPG was reduced by 1.6 mmol/L and 
2.4 mmol/L after 104 weeks of treatment with nate/met and 
glyb/met, respectively (p   0.0001 vs baseline for both groups, p 
  0.008 between groups), whereas PPG excursions, as assessed 
by the incremental AUC0-120min during an oral glucose tolerance 
test (OGTT), was reduced by 94 mmol/L•min and 57 mmol/
L•min after 104 weeks of treatment with nate/met and glyb/met, 
respectively (p   0.0001 vs baseline for nate/met, p = 0.0112 vs 
baseline for glyb/met, p = 0.0592 between groups).
Most of the AEs seen during the 2-year treatment period were 
those that would be expected to occur in an aging, overweight 
population (eg, arthralgia [10.5% of both treatment groups], 
or hypertension [8.7% nate/met, 14.8% glyb/met]). The only 
common ( 10%) AE that occurred predominantly (more than 
2-fold difference in prevalence) in either treatment group was 
hypoglycemia, which was reported by 8.2% of the patients 
receiving nate/met and 17.7% of the patients receiving glyb/met 
(p = 0.003). The only serious AE suspected to be related to treat-
ment was severe hypoglycemia that occurred in 2 patients receiv-
ing glyb/met. During 2-year treatment, there was a statistically 
signiﬁ  cant change in body weight between the groups. There was 
a modest increase in body weight in patients receiving glyb/met 
(Δ = +0.8 kg) and a small decrease in weight in patients receiving 
nate/met (Δ = –0.4 kg, p = 0.0115 vs glyb/met).
Another publication recently reported results from 
the subgroup of participants in PRESERVE-β who were 
aged  65 years of age (Schwarz et al 2008). This elderly 
subpopulation comprised 66 patients (33 patients in 
each treatment group), with a mean age, BMI, diabetes 
duration, HbA1c, and FPG of ∼70 years, 32 kg/m2, 2.1 years, 
7.8%, and 158 mg/dL, respectively. The elderly patients 
receiving glyb/met were somewhat more obese and had 
a somewhat longer duration of known diabetes than did 
the elderly patients receiving nate/met (BMI = 33.5 kg/m2 
vs 30.4 kg/m2, disease duration = 2.5 vs 1.7 years). After 
2 years of treatment, the change from baseline in HbA1c 
was -1.2% in both treatment groups (p   0.001 vs baseline 
for both treatments, p = 0.310 between treatments). Four-
teen of 20 (70%) elderly patients completing 2 years of 
nate/met combination therapy maintained HbA1c  7%, as 
did 13 of 20 (65%) elderly patients completing 2 years of 
glyb/met combination therapy. The change from baseline 
in FPG at study endpoint was –26 mg/dL and –36 mg/dL 
in patients receiving nate/met and glyb/met, respectively 
(p   0.001 vs baseline for both treatments, p = 0.234 
between treatments). The mean change in the PPG excur-
sion, as assessed by the incremental AUC0-120min during 
OGTT, approached statistical signiﬁ  cance in the nate/met 
group (Δ = –100 mmol/L•min, p = 0.071 vs baseline) 
but was considerably less in patients receiving glyb/met 
(Δ = –53 mmol/L•min, p = 0.385 vs baseline).
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The overall AE proﬁ  les in the 2 treatment groups were 
very similar except for the incidence of hypoglycemia, 
which was signiﬁ  cantly greater with glyb/met than with 
nate/met (p = 0.023). One incident of mild hypoglycemia 
occurred in one elderly patient receiving nate/met, while 
1 hypoglycemic episode occurred in each of 8 elderly patients 
receiving glyb/met; 4 were considered mild, 3 were consid-
ered moderate, and 1 was severe and led to discontinuation 
from the study.
Another blinded RCT compared the efﬁ  cacy and safety of 
nateglinide and gliclazide when added to metformin in patients 
with inadequate glycemic control (HbA1c between 6.8% and 
9.0%) on metformin monotherapy (Ristic et al 2006). This 
24-week, double-blind, double-dummy parallel-group study 
randomized 262 patients with T2DM, diagnosed at least 
6 months previously, receiving metformin monotherapy for at 
least 3 months, at their individually maximum tolerated dose 
( 1000 mg daily) for at least 2 months. Patients were also 
randomized to receive starting doses of nateglinide (60 mg 
ac, n = 133) or gliclazide (80 mg qd, n = 129), which were 
up-titrated monthly for the ﬁ  rst 3 months if FPG  7 mmol/L, 
to maximum doses of 180 mg ac for nateglinide or 240 mg 
qd for gliclazide. At baseline, the mean age, BMI, duration of 
diabetes, HbA1c, and FPG were ∼62 years, 30 kg/m2, 6.9 years, 
7.6%, and 8.8 mmol/L, respectively, and the treatment groups 
were well balanced with respect to these baseline charac-
teristics. At week 24 or study endpoint, the least squares 
mean change from baseline in HbA1c was –0.41% in patients 
receiving nateglinide and –0.57% in those receiving gliclazide 
(p   0.001 vs baseline for both groups, p = 0.099 between 
groups). At study endpoint, 35% of patients receiving nateg-
linide added to metformin and 47% of those receiving glicla-
zide added to metformin achieved HbA1c  7%. The decrease 
in FPG in patients receiving gliclazide (Δ = –0.8 mmol/L, 
p   0.001 vs baseline) was somewhat greater than that in 
patients receiving nateglinide (Δ = –0.6 mmol/L, p   0.001 
vs baseline), but this difference was not statistically signiﬁ  cant 
(p = 0.375). In contrast, PPG, as assessed by the maximum 
PPG excursion, was signiﬁ  cantly decreased only in the nateg-
linide group (Δ = –0.7 mmol/L [p = 0.001] and –0.1 mmol/L 
[p = 0.663] for nateglinide and gliclazide, respectively, 
p = 0.037 between groups).
The incidence of suspected drug-related AEs was low and 
similar in the 2 groups (6.9% and 7.1% for nateglinide and 
gliclazide, respectively). The percentages of patients with at 
least one AE suggestive of hypoglycemia (∼25%) or with at 
least one conﬁ  rmed hypoglycemic event (∼22%) were very 
similar in the 2 treatment groups. However, the percentage 
of patients with  3 conﬁ  rmed hypoglycemic events was 
somewhat higher with gliclazide (12.7%) than with nateg-
linide (9.2%). It should be noted that the plasma glucose 
cutoff for conﬁ  rmed hypoglycemia ( 4.0 mmol/L) was 
higher in this study than in previously described studies.
Results from a 6-month extension of the study described 
above (Ristic et al 2006) were reported recently (Ristic et al 
2007). A total of 120 patients in the nateglinide group and 
109 patients in the gliclazide group completed the study, and 
most of these patients continued with the double-blind exten-
sion (112 patients [93.3%] in the nateglinide group and 101 
patients [89.1%] in the gliclazide group). Glycemic control 
appeared to deteriorate somewhat during the 6-month exten-
sion, but qualitatively, the 1-year results mirrored the 6-month 
results. There was no signiﬁ  cant difference between treatment 
regimens in the Δ HbA1c from baseline to week 52 (–0.14% 
for nateglinide and –0.27 for gliclazide, p = 0.396 between 
groups); 40% of patients receiving nateglinide plus metfor-
min and 47.5% of those receiving gliclazide plus metformin 
achieved endpoint HbA1c  7%. The Δ FPG was somewhat 
greater in the gliclazide group (Δ = –0.7 mmol/L, p = 0.003 
vs baseline) than in the nateglinide group (Δ = –0.2 mmol/L, 
p = 0.357 vs baseline), but the between-treatment difference 
was not statistically signiﬁ  cant (p = 0.096). The change from 
baseline in the maximum PPG excursion was somewhat 
greater with nateglinide (Δ = –0.7 mmol/L, p = 0.087 vs 
baseline) than with gliclazide (Δ = –0.3 mmol/L, p = 0.500 
vs baseline), but, again, the between-treatment difference was 
not signiﬁ  cant (p = 0.470).
The AE proﬁ  les were similar in the 2 treatment groups 
during the extension, and a similarly low percentage of 
patients receiving natgelinide (6.3%) or gliclazide (6.9%) 
experienced  3 conﬁ  rmed episodes of hypoglycemia. There 
was a statistically signiﬁ  cant increase in body weight during 
the 52 weeks of study in patients receiving gliclazide plus met-
formin (Δ = 0.9 kg, p = 0.009 vs baseline); the change in body 
weight in the nateglinide plus metformin group was 0.4 kg 
and not statistically signiﬁ  cant (p = 0.201 vs baseline).
Results from a 1-year, double-blind, parallel-group RCT 
comparing initial combination therapy with nateglinide 
plus metformin (nate/met) vs glibenclamide plus metformin 
(glyb/met) were published recently (Derosa et al 2007). 
This study enrolled 248 treatment-naïve patients with 
T2DM diagnosed at least 6 months previously, who were 
overweight (BMI 25 kg/m2 to 28 kg/m2) and hypertensive 
( 130/85 mmHg). During the ﬁ  rst month, patients received 
either nateglinide (60 mg ac, n = 122) or glibenclamide 
(2.5 mg tid, n = 126). Metformin (500 mg tid) was added Vascular Health and Risk Management 2008:4(6) 1175
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during the second month of treatment in both groups 
of patients, and during the subsequent 4 months both 
metformin and the insulinotropic agent were up-titrated to 
maximum daily doses of nateglinide (360 mg, 120 mg ac) 
or glibenclamide (15 mg, 5 mg tid) plus metformin (3000 
mg, 1000 mg tid) if tolerated. The mean daily doses of 
nateglinide, glibenclamide, and metformin during the ﬁ  nal 6 
months of study were 300 ± 60 mg, 12.5 ± 2.5 mg, and 2500 
± 500 mg, respectively, with 119 patients receiving nate/met 
and 114 patients receiving glyb/met. Assessments of HbA1c, 
FPG, 2-hour PPG (after lunch), fasting lipids, blood pressure, 
and several prothrombotic factors were made periodically 
during the 12 months of treatment.
At baseline, the mean age, BMI, duration of diabetes, 
HbA1c, and FPG were ∼56 years, 26.5 kg/m2, 4.5 years, 8.2%, 
and 176 mg/dL, respectively, and the treatment groups were 
well-balanced with respect to these baseline characteristics. 
As summarized in Table 2, 1-year treatment of overweight, 
hypertensive, drug-naïve patients with T2DM with nate/met 
as initial combination therapy signiﬁ  cantly decreased HbA1c, 
FPG, and PPG as well as lipoprotein (a) (Lp[a]), plasminogen 
activator inhibitor-1 (PAI-1), and homocysteine levels rela-
tive to baseline. In patients receiving the glyb/met combina-
tion, a signiﬁ  cant decrease from baseline in HbA1c, FPG, and 
PPG was also seen after 12-month treatment; however, the 
improvement in HbA1c was signiﬁ  cantly less with glyb/met 
than with nate/met, and glyb/met had no signiﬁ  cant effect 
on any prothrombotic factor. Neither treatment signiﬁ  cantly 
affected any fasting lipid parameter, blood pressure, or BMI. 
No safety or tolerability assessments were reported, nor were 
the percentages of patients achieving endpoint HbA1c  7%. 
However, because the mean endpoint HbA1c with nate/met 
was 6.4% – while this was 7.3% in patients receiving glyb/
met – it may be inferred that a substantially higher percentage 
of patients receiving nate/met than glyb/met achieved this 
glycemic target.
Open-label trials
In addition to the blinded, RCTs of combination therapy 
with metformin and nateglinide, 3 open-label studies of this 
combination have also been reported. Schatz et al (2003) 
conducted a general practice observation study that followed 
11,476 patients with T2DM who were treated with nateg-
linide and metformin for 3 to 4 months (mean observation 
period = 96 days). The recommended dose of nateglinide 
was 120 mg before each principal meal. No recommended 
daily dose of metformin was provided, but the most common 
metformin regimen used in Germany, where this study was 
conducted, is 850 mg bid. The mean age, BMI, and HbA1c 
of patients in the study were 61.1 years, 29.4 kg/m2, and 
8.4%, respectively. Nearly all participants (98%) were 
already taking metformin when nateglinide was added. After 
the addition of nateglinide to metformin, mean HbA1c was 
reduced to 7.2% (p   0.0001 vs baseline) and, as expected, 
there was a direct relationship between the baseline value 
and the magnitude of reduction in HbA1c over the course of 
treatment. At baseline, only 11.1% of the patients had HbA1c 
 7%, but by the end of the treatment period 47.7% of patients 
had achieved this goal. PPG was also measured following a 
standardized breakfast or during an OGGT. During the treat-
ment period, mean 2-hour PPG decreased from 210 mg/dL 
to 152 mg/dL (p   0.0001).
Addition of nateglinide to metformin was also associated 
with signiﬁ  cant improvement in both diastolic and systolic 
blood pressure and resulted in a small (1.5 kg) but signiﬁ  cant 
reduction in body weight. Overall, AEs were reported in 
277 patients (2.9%) and severe AEs in 56 patients (0.5%). 
Hypoglycemic episodes were seen in 30 patients (0.3%).
Table 2 Effects of initial combination therapy with nateglinide (Nate) or glibenclamide (Glyb) plus metformin (Met) on glycemic control 
and prothrombotic factors during 1-year treatment of overweight and hypertensive patients with type 2 diabetes (Derosa et al 2007)
Nate/Met Glyb/Me
Mean ± SD Baseline 12 months Baseline 12 months
HbA1c (%) 8.1 ± 1.0 6.4 ± 0.4b,c 8.2 ± 1.1 7.3 ± 0.6a
FPG (mg/dL) 174 ± 21 138 ± 17b 177 ± 24 136 ± 15b
2-hour PPG (mg/dL) 191 ± 28 150 ± 21b 187 ± 24 166 ± 20a
Lp(a) (mg/dL) 29.3 ± 18.9 20.1 ± 14.2a,c 28.5 ± 17.4 26.7 ± 16.9
PAI-1 (ng/mL) 44.5 ± 15.9 36.1 ± 13.1a,c 43.9 ± 16.2 41.3 ± 15.6
Homocysteine (μM) 13.6 ± 2.4 9.2 ± 1.8a,c 13.9 ± 2.6 12.7 ± 2.2
ap   0.05 vs baseline, bp   0.01 vs baseline, cp   0.05 vs glib/met.
Abbreviations: Nate, nateglinide; Glyb, glibenclamide; Met, metformin; FPG, fasting plasma glucose; PPG, postprandial glucose; Lp(a), lipoprotein (a); PAI-1,  plasminogen activator 
inhibitor-1; HbA1c glycosylated hemoglobin.Vascular Health and Risk Management 2008:4(6) 1176
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In an open-label, randomized, parallel-group, multicenter 
study, Raskin et al (2003) compared the efﬁ  cacy and safety 
of nateglinide and repaglinide when added to metformin. 
Enrolled patients (N = 192) had diagnosed T2DM for at 
least 3 months and had HbA1c values  7% and  12% during 
previous monotherapy with sufonylurea, metformin, or low-
dose glyburide/metformin. During a 4-week run-in period, 
all patients previously taking sulfonylurea or glyburide/
metformin were switched to metformin. All patients on 
metformin were titrated to a maximum dose of 1000 mg bid 
and then randomized to receive either nateglinide (120 mg ac) 
or repaglinide (1 mg ac titrated to a maximum of 4 mg ac). 
After the 2-week titration period, the combination therapies 
were continued for an additional 14 weeks.
At baseline, the mean age, BMI, disease duration, HbA1c, 
and FPG were 55.4 years, 33.2 kg/m2, 6.9 years, 8.3%, and 
190 mg/dL, respectively. The groups were well balanced 
with respect to age, BMI, and FPG, but the mean disease 
duration was somewhat longer in patients randomized to 
nateglinide/metformin (7.1 years) than in those randomized 
to repaglinide/metformin (6.7 years) and HbA1c was some-
what higher in the repaglinide/metformin group (8.4%) than 
in the nateglinide/metformin group (8.2%).
The mean change from baseline in HbA1c was −1.3% with 
repaglinide and −0.7% with nateglinide added to metformin 
(p   0.001 between groups). At study endpoint, 59% of 
patients receiving repaglinide and 47% of those receiving 
nateglinide achieved HbA1c  7%. The mean decrease in FPG 
was also signiﬁ  cantly greater with repaglinide/metformin 
than with nateglinide/metformin (–39 mg/dL vs –21 mg/dL, 
p = 0.002). However, the mean reductions in PPG did not 
differ between groups.
Hypoglycemic episodes were reported by 7% of patients 
receiving repaglinide/metformin and by 2% of those 
receiving nateglinide/metformin. However, no severe hypo-
glycemia occurred in either group. Otherwise, there were no 
noteworthy differences in the AE proﬁ  les in the 2 treatment 
groups. The mean change in body weight was +0.6 kg 
with repaglinide/metformin and –0.5 kg with nateglinide/
metformin (statistical signiﬁ  cance not reported).
It should be noted that the generalizability of the 
conclusions drawn by Raskin et al (2003) has been ques-
tioned because of limitations of the study design (Baron 
2003). These include the fact that metformin was titrated to 
the ﬁ  nal dose (2 g/day) over only 4 weeks, which may not 
be an adequate time for glycemic control to stabilize and to 
establish a reliable baseline. Another limitation is that more 
than 33% of patients receiving nateglinide/metformin had 
previously been treated with a sulfonylurea. Sulfonylureas 
are known to blunt the efﬁ  cacy of nateglinide; at the time of 
this study, the nateglinide label stated that patients should 
not be switched from a sulfonylurea to nateglinide. Thus, a 
substantial proportion of patients in the nateglinide/metfor-
min group was treated outside of the product labeling.
Another open-label, 12-week study included a group 
of patients who received nateglinide (120 mg ac, n = 214) 
added to a stable dose of metformin (Weaver et al 2004). At 
baseline, mean age, BMI, duration of known diabetes, HbA1c, 
and FPG were ∼60 years (range = 37–84 years), 32.6 kg/m2, 
5 years, 8.1%, and 10.0 mmol/L, respectively. The changes 
from baseline to week 12 of treatment with nateglinide 
added to ongoing metformin monotherapy in HbA1c, FPG, 
and 2-hour PPG averaged –0.7% mmol/L, –0.8 mmol/L, 
and –2.4 mmol/L, respectively (p   0.0001 vs baseline for 
each efﬁ  cacy parameter). Only 2% of patients who received 
nateglinide added to metformin had HbA1c  7% at baseline, 
while 34% achieved this goal after 12 weeks’ treatment.
In patients receiving nateglinide added to metformin, 
14% experienced symptoms consistent with hypogly-
cemia, but no conﬁ  rmatory glucose measurements were 
reported. None of the suspected hypoglycemic episodes 
required assistance from an outside party. Serious AEs 
were reported by 3 patients (1.4%), but only 1 of these was 
suspected to be related to study medication. The authors 
concluded that nateglinide added to metformin was safe and 
effective in patients up to 84 years of age.
Summary and conclusions
T2DM is difﬁ  cult to control with a single oral agent and the 
rate of monotherapy failure is high, so combination therapy 
with complementary classes of drugs that act on different 
aspects of glycemic control would be expected to be an 
effective strategy. The present work reviewed all published 
information about the efﬁ  cacy and safety/tolerability of nateg-
linide when combined with metformin in patients with T2DM, 
whether given as initial combination therapy or as an add-on to 
ongoing metformin monotherapy. Because metformin acts by 
suppressing excessive HGP and improving glucose clearance, 
its predominant effect is to decrease FPG. Nateglinide, which 
is taken before main meals, serves to restore the early phase 
of insulin release that is lost relatively soon after the onset of 
diabetes, and thus limits PPG excursions that have been impli-
cated in the cardiovascular risk associated with T2DM.
Both metformin and nateglinide are known to have a low 
propensity to elicit hypoglycemia. The known side effects 
of metformin (ie, gastrointestinal symptoms such as diarrhea Vascular Health and Risk Management 2008:4(6) 1177
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and abdominal discomfort) generally occur only early in the 
course of treatment and can be minimized by dose titration. 
Nateglinide has an excellent safety and tolerability proﬁ  le 
and does not require dose titration. Accordingly, it is not 
surprising that the published literature supports a conclusion 
that these drugs, when combined, are safe, well tolerated, and 
produce a degree of long-term glycemic control that is not 
achievable with either agent alone. The largest decreases in 
HbA1c (Δ = –1.4% to –1.9%, sustained for up to 2 years) are 
seen in drug-naïve patients given metformin ( 1500 mg/day) 
and nateglinide (120 mg ac) as initial combination therapy. 
Lesser, but still clinically-signiﬁ  cant decreases (Δ = –0.5% to 
–1.2%) are seen when nateglinide is added to ongoing stable 
metformin monotherapy. With either of these approaches, the 
decrease in HbA1c is proportional to the baseline level. The 
percentage of patients receiving the nateglinide/metformin 
combination and achieving HbA1c  7% has ranged from 35% 
to 70%. In studies of initial combination therapy, nateglinide/
metformin has been found to be as effective, or more effec-
tive, than sulfonylureas (glyburide or glicazide) combined 
with metformin. However, in one open-label study of add-on 
to (recently initiated) metformin therapy, repaglinide was 
found to be more effective than nateglinide. In all reports, the 
nateglinide/metformin combination was found to be safe and 
well tolerated, and to have a very low hypoglycemic potential. 
In all studies where nateglinide/metformin was compared to 
metformin combined with any insulinotropic agent, hypogly-
cemia was less frequent and changes in body weight were 
smaller with the nateglinide/metformin combination.
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